Purchase Order 75N93020P01033

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. valued at $1,147,346.00 on September 26, 2019, for customized biologicals under firm fixed pricing. Performance is located in Piscataway, New Jersey. The order has no small business set-aside and carried an ultimate completion date of September 25, 2020. The originating pre-solicitation was posted September 3, 2019, with a due date of September 6, 2019.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for antibody gene synthesis and production, valued at $16,974.27, on August 26, 2020. The order was firm fixed price with an ultimate completion date of February 6, 2021. Work was performed at Genscript's facility in Piscataway, New Jersey.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $14,756.36 on September 13, 2021, for sequencing services under the FY26 UDO Initiative. Performance is at Genscript's facility in Piscataway, New Jersey. The order carries a firm fixed price and was completed by December 31, 2021.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. on September 3, 2022, for gene synthesis plasmid preparation services, with a firm fixed price ceiling of $48,665.65. Place of performance is Piscataway, New Jersey. The work supports the FY26 UDO Initiative and was sourced through a pre-solicitation opportunity posted August 24, 2022, with a September 2 deadline. Ultimate completion is scheduled for September 29, 2022.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $15,028.93 on September 10, 2015, for mutagenesis, gene synthesis, custom plasmid preparation, and reagents. Work is performed in Piscataway, New Jersey. The order carries a firm fixed price and no set-aside designation. Ultimate completion is September 13, 2016.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for sequencing and gene synthesis services for 100 samples on March 17, 2022, with a ceiling value of $15,389.60. Work is performed in Piscataway, New Jersey. The order is firm fixed price with no set-aside designation and an ultimate completion date of March 16, 2023.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for $17,209.00 on September 18, 2023, for custom gene synthesis and expression services. Performance occurs in Bethesda, Maryland. The order is firm fixed price with no small business set-aside. The ultimate completion date is December 31, 2023.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. valued at $14,979.75 on August 29, 2024, for monoclonal antibodies and plasmids services. The order is firm fixed price with no small business set-aside. Performance occurs in Piscataway, New Jersey. The modification de-obligates excess funds, with ultimate completion scheduled for May 18, 2026.</p>

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases has awarded a $20,827.75 purchase order to Genscript USA Inc. to provide customized protein production using a baculovirus expression system. Performance will take place in Piscataway, New Jersey over a period of approximately three months concluding in mid-December 2023. The firm fixed price contract calls for Genscript to deliver the requested proteins without further...

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Genscript USA Inc. for customized monoclonal antibody on June 27, 2018, with a ceiling value of $30,289.88 and firm fixed pricing. Performance is located in Piscataway, New Jersey, with an ultimate completion date of July 10, 2018. No small business set-aside was used.</p>